MK-3222: Phase III started

Merck disclosed in its 4Q12 earnings that it began a 64-week, double-blind, placebo-controlled Phase

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE